公开(公告)号：US20210189504A1

公开(公告)日：2021-06-24

申请号：US17186422

申请日：2021-02-26

Applicant: KABUSHIKI KAISHA TOSHIBA

Inventor： Koji HASHIMOTO ,  Mika INADA ,  Keiko ITO

IPC: C12Q1/6886

Abstract: According to the embodiments, miRNA having a nucleotide sequence represented by SEQ ID NO: 1 is used as a marker for cancer diagnosis. For example, a method for diagnosing cancer in a subject, comprising the step of: measuring the amount of RNA having the nucleotide sequence in a biological sample is disclosed.

公开(公告)号：US20180274022A1

公开(公告)日：2018-09-27

申请号：US15908044

申请日：2018-02-28

Applicant: KABUSHIKI KAISHA TOSHIBA

Inventor： Mika INADA ,  Koji Hashimoto ,  Keiko Ito

IPC: C12Q1/6853

CPC classification number: C12Q1/6853 ,  C12Q2521/107 ,  C12Q2525/101 ,  C12Q2525/207 ,  C12Q2527/101

Abstract: In general, according to one embodiment, a method containing, reverse-transcribing the first sequence in the target RNA, to obtain a reverse-transcription product containing a first′ sequence complementary to the first sequence, dissociating the reverse-transcription product from the target RNA, hybridizing an elongation primer and the reverse-transcription product to elongate both, thereby obtain an elongation product, and maintaining the amplification reaction liquid containing the elongation product, a primer set and Tin(exo-) DNA polymerase and/or Bsm DNA polymerase under an amplification reaction condition, to amplify the first′ sequence.

公开(公告)号：US20210404017A1

公开(公告)日：2021-12-30

申请号：US17472118

申请日：2021-09-10

Applicant: KABUSHIKI KAISHA TOSHIBA

Inventor： Mika INADA ,  Koji HASHIMOTO

IPC: C12Q1/6886

Abstract: According to one embodiment, there is provided an analytical method for determining the presence or absence of contraction of cancer in a subject. The method includes quantifying hsa-miR-1301-3p in a sample originating from the subject.

公开(公告)号：US20210214804A1

公开(公告)日：2021-07-15

申请号：US17188101

申请日：2021-03-01

Applicant: KABUSHIKI KAISHA TOSHIBA

Inventor： Koji HASHIMOTO ,  Mika INADA ,  Keiko ITO

IPC: C12Q1/6886

Abstract: In general, according to one embodiment, analytical method for determining the presence/absence of the contraction of the pancreatic cancer in subjects is provided. The method comprises quantifying hsa-miR-122-5p in a sample originated from a subject.

公开(公告)号：US20210139968A1

公开(公告)日：2021-05-13

申请号：US17154267

申请日：2021-01-21

Applicant: KABUSHIKI KAISHA TOSHIBA

Inventor： Mika INADA ,  Koji HASHIMOTO ,  Keiko ITO

IPC: C12Q1/6853

Abstract: In general, according to one embodiment, a method containing, reverse-transcribing the first sequence in the target RNA, to obtain a reverse-transcription product containing a first' sequence complementary to the first sequence, dissociating the reverse-transcription product from the target RNA, hybridizing an elongation primer and the reverse-transcription product to elongate both, thereby obtain an elongation product, and maintaining the amplification reaction liquid containing the elongation product, a primer set and Tin(exo-) DMA polymerase and/or Bsm DMA polymerase under an amplification reaction condition, to amplify the first' sequence.

公开(公告)号：US20210079457A1

公开(公告)日：2021-03-18

申请号：US17095139

申请日：2020-11-11

Applicant: KABUSHIKI KAISHA TOSHIBA

Inventor： Koji HASHIMOTO ,  Keiko ITO ,  Mika INADA

IPC: C12Q1/6851 ,  B01L3/00

Abstract: According to one embodiment, a method of quantifying a target nucleic acid containing a first sequence in a sample is provided. The method includes preparing a substrate on which a plurality of detection regions are arranged, forming a reaction field by placing, on the substrate, a reaction liquid containing a sample, a primer set, and an amplification enzyme, maintaining the reaction field in an isothermal amplification condition, detecting a detection signal for each of the detection regions, determining, for each of the plurality of detection regions, whether positive or negative and detecting or quantifying the target nucleic acid based on the number of positive and/or a rise time of each of the positive detection signal.

公开(公告)号：US20220154261A1

公开(公告)日：2022-05-19

申请号：US17649568

申请日：2022-02-01

Applicant: KABUSHIKI KAISHA TOSHIBA

Inventor： Koji HASHIMOTO ,  Keiko ITO ,  Mika INADA

IPC: C12Q1/6837 ,  C12Q1/6823 ,  C12Q1/6825 ,  C12Q1/6851

Abstract: According to one embodiment, a method for detecting target nucleic acid includes the following steps. (A) A reaction field is formed by placing a reaction mixture on an electrode, and the reaction mixture contains the sample, a primer set, an amplification enzyme, 4 mM to 30 mM of magnesium ion, and a redox probe. The redox probe has an oxidation reduction potential, which generates an electric signal of which amplitude increases. (B) The reaction field is maintained under an amplification reaction condition. (C) The electric signal is detected with the electrode. (D) Existence or quantity of the target nucleic acid is determined.

公开(公告)号：US20210214805A1

公开(公告)日：2021-07-15

申请号：US17189372

申请日：2021-03-02

Applicant: KABUSHIKI KAISHA TOSHIBA

Inventor： Mika INADA ,  Koji HASHIMOTO ,  Keiko ITO

IPC: C12Q1/6886

Abstract: According to one embodiment, analytical method for determining the presence/absence of the contraction of the prostatic cancer in subjects is provided. The method comprises quantifying hsa-miR-92a-3p in a sample originated from a subject.

公开(公告)号：US20210207215A1

公开(公告)日：2021-07-08

申请号：US17172378

申请日：2021-02-10

Applicant: KABUSHIKI KAISHA TOSHIBA

Inventor： Keiko ITO ,  Mika INADA ,  Koji HASHIMOTO

IPC: C12Q1/6876 ,  C12P19/34 ,  C12N15/10 ,  C12Q1/6848

Abstract: According to one embodiment, a primer set for elongating a target short-chain nucleic acid containing a first sequence to obtain an elongated product is provided. The elongated product contains a second, a third, a fourth sequence, a complementary sequence of the 1′-th sequence and a sixth sequence. The complementary sequence of the 1′-th sequence is a loop primer sequence. The primer set contains a first elongation primer containing a first elongation primer sequence and a complementary sequence of the sixth sequence, and a second elongation primer containing a second elongation primer sequence, the fourth, the third, and the second sequence.